Lb Pharmaceuticals (LBRX) Net Income towards Common Stockholders (2024 - 2026)

Lb Pharmaceuticals' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$19.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 259.1% year-over-year to -$19.1 million; the TTM figure through Mar 2026 stood at -$14.2 million (changed N/A YoY), while the FY2025 annual figure was -$25205.0, up 60.06% from the prior year.
• Net Income towards Common Stockholders was -$19.1 million for Q1 2026 at Lb Pharmaceuticals, down from $13.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $58.0 million in Q4 2024 to a low of -$19.1 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged $4.9 million across 3 years, with a median of -$4.4 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders jumped 74.92% in 2025, then slumped 259.1% in 2026.
• A 3-year view of Net Income towards Common Stockholders shows it stood at $58.0 million in 2024, then tumbled by 76.35% to $13.7 million in 2025, then sank by 239.0% to -$19.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$19.1 million (Q1 2026), $13.7 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.